Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
44
-
Total 13F shares, excl. options
-
11.8M
-
Shares change
-
+252K
-
Total reported value, excl. options
-
$22.2M
-
Value change
-
+$477K
-
Number of buys
-
21
-
Number of sells
-
-16
-
Price
-
$1.88
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q2 2020
55 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q2 2020.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 44 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 11.8M shares
of 77M outstanding shares and own 15.3% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (3.92M shares), Carmignac Gestion (1.94M shares), VANGUARD GROUP INC (1.59M shares), RENAISSANCE TECHNOLOGIES LLC (811K shares), BlackRock Inc. (756K shares), GROUP ONE TRADING, L.P. (568K shares), GEODE CAPITAL MANAGEMENT, LLC (326K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (184K shares), FIRST MANHATTAN CO (175K shares), and Tekla Capital Management LLC (165K shares).
This table shows the top 44 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.